THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,328,244 | -34.0% | 269,785 | -20.8% | 0.00% | -100.0% |
Q2 2023 | $3,525,200 | -3.4% | 340,599 | +1.2% | 0.00% | 0.0% |
Q1 2023 | $3,650,233 | -17.8% | 336,427 | -15.0% | 0.00% | 0.0% |
Q4 2022 | $4,442,929 | -34.9% | 395,983 | -41.1% | 0.00% | 0.0% |
Q3 2022 | $6,822,000 | +29.2% | 672,859 | +15.4% | 0.00% | 0.0% |
Q2 2022 | $5,282,000 | -43.4% | 583,029 | -40.3% | 0.00% | -50.0% |
Q1 2022 | $9,335,000 | +145.7% | 976,373 | +184.0% | 0.00% | +100.0% |
Q4 2021 | $3,799,000 | +68.7% | 343,791 | +13.0% | 0.00% | – |
Q3 2021 | $2,252,000 | -46.1% | 304,257 | +5.7% | 0.00% | -100.0% |
Q2 2021 | $4,179,000 | -27.2% | 287,759 | +2.4% | 0.00% | 0.0% |
Q1 2021 | $5,737,000 | -7.6% | 281,120 | -19.6% | 0.00% | -50.0% |
Q4 2020 | $6,210,000 | +33.3% | 349,509 | +10.9% | 0.00% | +100.0% |
Q3 2020 | $4,660,000 | -33.5% | 315,165 | -5.6% | 0.00% | -50.0% |
Q2 2020 | $7,010,000 | +78.2% | 333,945 | +96.2% | 0.00% | +100.0% |
Q1 2020 | $3,934,000 | +30.3% | 170,210 | +45.9% | 0.00% | 0.0% |
Q4 2019 | $3,020,000 | +31.0% | 116,648 | -1.4% | 0.00% | 0.0% |
Q3 2019 | $2,305,000 | -42.4% | 118,329 | -51.7% | 0.00% | 0.0% |
Q2 2019 | $4,005,000 | -33.6% | 245,218 | -7.8% | 0.00% | -50.0% |
Q1 2019 | $6,028,000 | +0.3% | 265,889 | +13.2% | 0.00% | 0.0% |
Q4 2018 | $6,009,000 | -16.1% | 234,818 | +7.1% | 0.00% | 0.0% |
Q3 2018 | $7,166,000 | +42.0% | 219,343 | -1.4% | 0.00% | +100.0% |
Q2 2018 | $5,047,000 | -55.7% | 222,525 | -52.7% | 0.00% | -66.7% |
Q1 2018 | $11,403,000 | +106.9% | 470,217 | +137.9% | 0.00% | +200.0% |
Q4 2017 | $5,512,000 | -37.3% | 197,618 | -23.0% | 0.00% | -50.0% |
Q3 2017 | $8,793,000 | -7.7% | 256,808 | +7.4% | 0.00% | 0.0% |
Q2 2017 | $9,528,000 | +1.0% | 239,176 | -6.6% | 0.00% | -33.3% |
Q1 2017 | $9,430,000 | +409.5% | 256,110 | +341.2% | 0.00% | +200.0% |
Q4 2016 | $1,851,000 | +94.0% | 58,048 | +120.6% | 0.00% | – |
Q3 2016 | $954,000 | +165.0% | 26,312 | +65.7% | 0.00% | – |
Q2 2016 | $360,000 | +31.9% | 15,882 | +9.2% | 0.00% | – |
Q1 2016 | $273,000 | -11.7% | 14,547 | -22.8% | 0.00% | – |
Q4 2015 | $309,000 | +87.3% | 18,835 | +25.3% | 0.00% | – |
Q3 2015 | $165,000 | -29.5% | 15,030 | +104.6% | 0.00% | – |
Q2 2014 | $234,000 | – | 7,346 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Woodford Investment Management Ltd | 10,898,879 | $264,297,000 | 23.51% |
Foundation Asset Management, LP | 399,537 | $9,689,000 | 3.59% |
Cormorant Asset Management, LP | 1,300,000 | $31,525,000 | 2.35% |
Baupost Group | 9,309,168 | $225,747,000 | 2.18% |
Old West Investment Management, LLC | 109,320 | $2,651,000 | 1.53% |
SENZAR ASSET MANAGEMENT, LLC | 187,856 | $4,555,000 | 1.44% |
Chescapmanager LLC | 350,631 | $8,503,000 | 1.27% |
Virtus ETF Advisers LLC | 32,989 | $800,000 | 0.69% |
Rock Springs Capital Management LP | 652,600 | $15,826,000 | 0.68% |
NJ State Employees Deferred Compensation Plan | 34,142 | $828,000 | 0.15% |